Contact us   |  

Treatment of anemia of low risk myelodysplastic syndrome (FDA approval of Luspatercept in LR-MDS)

Treatment of anemia of low risk myelodysplastic syndrome (FDA approval of Luspatercept in LR-MDS)

14/11/2024 17:00

Speakers: Uwe Platzbecker

Target: Health professionals
Subnetworks: Myeloid malignancies
Disease Groups: Myelodysplastic syndrome

Pr. Uwe Platzbecker serves as the Director of the Clinic and Polyclinic for Hematology, Cell Therapy, and Hemostaseology at Leipzig University Hospital in Leipzig, Germany. He completed his medical education at the Technical University of Dresden, also in Germany.

Pr. Platzbecker's research is primarily dedicated to myelodysplastic syndromes (MDS) and its treatment. His team has conducted trials on luspatercept and imetelstat for patients with lower-risk MDS, as well as a recent Phase I trial investigating a new oral IRAK4 inhibitor for relapsed/refractory high-risk MDS or acute myeloid leukemia.

Registration is closed for this webinar